From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 3
Total Number 3
Disease Relevance 2.43
Pain Relevance 0.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (PDGFRA) nucleus (PDGFRA) extracellular matrix organization (PDGFRA)
cytoplasm (PDGFRA)
Anatomy Link Frequency
thyroid 1
platelet 1
PDGFRA (Homo sapiens)
Pain Link Frequency Relevance Heat
Dysuria 1 83.56 Quite High
positron emission tomography 1 47.44 Quite Low
palliative 1 25.36 Quite Low
pain flank 1 19.00 Low Low
imagery 2 5.00 Very Low Very Low Very Low
cytokine 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Renal Cancer 15 98.04 Very High Very High Very High
Metastasis 6 97.28 Very High Very High Very High
Small Cell Lung Cancer 5 96.20 Very High Very High Very High
Carcinoma 1 85.40 High High
Leukemia 2 83.04 Quite High
Philadelphia Chromosome 1 80.88 Quite High
Disease 5 75.84 Quite High
Malignant Neoplastic Disease 4 75.12 Quite High
Skin Cancer 5 75.00 Quite High
Gastrointestinal Stromal Tumor 2 72.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Immunohistochemistry of the tumorectomy and autopsy specimens was positive for cytokeratins, neuron-specific enolase, synaptophysin, CD56, KIT and PDGFRA, and negative for chromogranin and thyroid transcriptional factor-1.
Negative_regulation (positive) of PDGFRA in thyroid
1) Confidence 0.43 Published 2009 Journal Pathol. Int. Section Abstract Doc Link 19351368 Disease Relevance 0.61 Pain Relevance 0.08
Sunitinib malate is an oral multi-kinase inhibitor targeting several receptor tyrosine kinases (PDGFRalpha and PDGFRbeta; VEGFR1, VEGFR2 and VEGFR3; KIT, FLT3, CSF-1R and RET) that was approved by the FDA in 2006 for treatment of metastatic renal cell carcinoma.
Negative_regulation (inhibitor) of PDGFRalpha associated with renal cancer
2) Confidence 0.41 Published 2010 Journal World J Surg Oncol Section Body Doc Link PMC2890518 Disease Relevance 0.96 Pain Relevance 0
Imatinib mesylate (IM), is a selective and competitive inhibitor of tyrosine kinases, including BCR-ABL, ABL, KIT, and the platelet-derived growth factor receptors (PDGF-R).
Negative_regulation (inhibitor) of PDGF-R in platelet
3) Confidence 0.38 Published 2003 Journal J. Exp. Clin. Cancer Res. Section Abstract Doc Link 16767900 Disease Relevance 0.86 Pain Relevance 0

General Comments

This test has worked.

Personal tools